Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_1375_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
15.09.2026
Размер:
11 Мб
Скачать
☆
376
preservation particularly for low- and mid-rectal lesions [35]. Outcomes are also collected in the taTME registry hosted by the OSTRiCh (Optimizing Surgical Treatment of Rectal Cancer) national clinical collaborative [36].
J. Fleshman and K. Wells
National Accreditation Program forRectal Cancer (NAPRC)
Whatever the advances in operative techniques for rectal cancer surgery, complete TME remains the goal. Dening operative benchmarks and establishing accredita­tion of complex/high-risk operations to specialized centers is the way to standardize a high level of quality via real-time auditing. Through OSTRiCh recommendations to the ACS Commission on Cancer (CoC), the National Accreditation Program for Rectal Cancer (NAPRC) was developed to employ a multidisciplinary, evidence­based approach to guide the processes of rectal cancer care [37].
Part of this process includes designation of high-risk procedures, including TME, to specialized centers with high-volume surgeons to ensure that surgical standards are consistently achieved. This is controversial as the absolute number of cases needed to overcome the learning curve for prociency remains unclear. Historically, high-volume surgeons (>20 cases) had fewer complications and need for post­procedural interventions compared to lower-volume surgeons [38]. A more recent database analysis supports that surgeons with a cumulative 5-year experience of >25 rectal resections had signicantly lower rates of major events (OR=0.82) and surgi­cal complications (OR 0.71) [39]. There are very few reports on the learning curve for laparoscopic resection of the rectum. In the randomized controlled trials outlined above, high volume was a requirement for participation. Z6051 required that sur­geons be credentialed for laparoscopic and open TME rectal resection and submit 20 operative and path reports as well as an unedited recording of a laparoscopic pelvic dissection for review. ROLARR required 30 rectal cancer resections per surgeon prior to credentialing. Certainly the excellent results reported in recent literature have become the expectation for clinical practice, and colorectal surgeons who intend to manage rectal cancer should, therefore, undergo the same degree of scrutiny.

Conclusions

Total mesorectal excision through a minimally invasive approach is feasible in the hands of the experienced surgeon. Currently short-term outcomes through mini­mally invasive techniques approach those of open resection; however, we await oncologic outcomes and meta-analysis of the most recent randomized controlled trials. Until then, laparoscopic TME should be used judiciously. Emerging tech­nologies including robotic surgery and taTME offer alternative strategies for achiev­ing the goal of a high-quality oncologic resection. As the landscape of rectal cancer surgery evolves, the necessary constant needs to be multidisciplinary oversight with rectal cancer surgery limited to a body of surgeons and surgical centers experienced in this high-risk procedure.
32 Laparoscopic TME: Is There aVerdict?
377

References

1. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to
pelvic recurrence? Br JSurg. 1982;69(10):613–6.
2. Fleshman J, Branda M, Sargent DJ, Boller AM, George V, Abbas M, et al. Effect of
laparoscopic- assisted resection vs open resection of stage II or III rectal cancer on pathologic outcomes. JAMA. 2015;314(13):1346.
3. Stevenson ARL, Solomon MJ, Lumley JW, Hewett P, Clouston AD, Gebski VJ, etal. Effect of
laparoscopic-assisted resection vs open resection on pathological outcomes in rectal cancer. JAMA. 2015;314(13):1356.
4. Fleshman JW, Wexner SD, Anvari M, LaTulippe JF, Birnbaum EH, Kodner IJ, etal. Laparoscopic
vs. open abdominoperineal resection for cancer. Dis Colon Rectum. 1999;42(7):930–9.
5. Feliciotti F, Guerrieri M, Paganini AM, De Sanctis A, Campagnacci R, Perretta S, et al.
Long-term results of laparoscopic versus open resections for rectal cancer for 124 unselected patients. Surg Endosc. 2003;17(10):1530–5.
6. Vennix S, Pelzers L, Bouvy N, Beets GL, Pierie J-P, Wiggers T, etal. Laparoscopic versus open
total mesorectal excision for rectal cancer. Cochrane Database Syst Rev. 2014;58(4):CD005200.
7. Guillou PJ, Quirke P, Thorpe H, Walker J, Jayne DG. Short-term endpoints of conventional
versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet. 2005;365(9472):1718–26.
8. Green BL, Marshall HC, Collinson F, Quirke P, Guillou P, Jayne DG, etal. Long-term follow-
up of the Medical Research Council CLASICC trial of conventional versuslaparoscopically assisted resection in colorectal cancer. Br JSurg. 2012;100(1):75–82.
9. Bonjer HJ, Deijen CL, Abis GA, Cuesta MA, van der Pas MHGM, de Lange-de Klerk ESM,
etal. A randomized trial of laparoscopic versus open surgery for rectal cancer. N Engl JMed. 2015;372(14):1324–32.
10. Pas MHGM, Deijen CL, Abis GSA, Klerk ESML-D, Haglind E, Fürst A, etal. Conversions in
laparoscopic surgery for rectal cancer. Surg Endosc. 2016;31(5):2263–70.
11. Kang S-B, Park JW, Jeong S-Y, Nam BH, Choi HS, Kim D-W, et al. Open versus laparo-
scopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial. Lancet Oncol. 2010;11(7):637–45.
12. Jeong S-Y, Park JW, Nam BH, Kim S, Kang S-B, Lim S-B, etal. Open versus laparoscopic
surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy(COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. Lancet Oncol. 2014;15(7):767–74.
13. Zheng J, Feng X, Yang Z, Hu W, Luo Y, Li Y.The comprehensive therapeutic effects of rec-
tal surgery are better in laparoscopy: a systematic review and meta-analysis. Oncotarget. 2017;8(8):12717–29.
14. Strouch MJ, Zhou G, Fleshman JW, Birnbaum EH, Hunt SR, Mutch MG.Time to initiation of
postoperative chemotherapy. Dis Colon Rectum. 2013;56(8):945–51.
15. Celentano V, Cohen R, Warusavitarne J, Faiz O, Chand M.Sexual dysfunction following rectal
cancer surgery. Int JColor Dis. 2017;32(11):1523–30.
16. Jayne DG, Brown JM, Thorpe H, Walker J, Quirke P, Guillou PJ.Bladder and sexual function
following resection for rectal cancer in a randomized clinical trial of laparoscopicversus open technique. Br JSurg. 2005;92(9):1124–32.
17. Andersson J, Abis G, Gellerstedt M, Angenete E, Angerås U, Cuesta MA, et al. Patient-
reported genitourinary dysfunction after laparoscopic and open rectal cancer surgery in a ran­domized trial (COLOR II). Br JSurg. 2014;101(10):1272–9.
18. Pigazzi A, Ellenhorn JDI, Ballantyne GH, Paz IB.Robotic-assisted laparoscopic low anterior
resection with total mesorectal excision for rectal cancer. Surg Endosc. 2006;20(10):1521–5.
19. Speicher PJ, Englum BR, Ganapathi AM, Nussbaum DP, Mantyh CR, Migaly J.Robotic low
anterior resection for rectal cancer. Ann Surg. 2015;262(6):1040–5.
378
20. Baik SH, Kwon HY, Kim JS, Hur H, Sohn SK, Cho CH, etal. Robotic versus laparoscopic
low anterior resection of rectal cancer: short-term outcome of a prospective comparative study. Ann Surg Oncol. 2009;16(6):1480–7.
21. Kim MJ, Park SC, Park JW, Chang HJ, Kim DY, Nam BH, etal. Robot-assisted versus laparo-
scopic surgery for rectal cancer: a phase II open label prospective randomized controlled trial. Ann Surg. 2017. https://doi.org/10.1097/SLA.0000000000002321. [Epub ahead of print].
22. Saklani AP, Lim DR, Hur H, Min BS, Baik SH, Lee KY, et al. Robotic versus laparoscopic
surgery for mid–low rectal cancer after neoadjuvant chemoradiation therapy: comparison of oncologic outcomes. Int JColor Dis. 2013;28(12):1689–98.
23. Baek SJ, AL-Asari S, Jeong DH, Hur H, Min BS, Baik SH, etal. Robotic versus laparoscopic
coloanal anastomosis with or without intersphincteric resection for rectal cancer. Surg Endosc. 2013;27(11):4157–63.
24. Collinson FJ, Jayne DG, Pigazzi A, Tsang C, Barrie JM, Edlin R, etal. An international, multi-
centre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus standard laparoscopic surgery for the curative treatment of rectal cancer. Int JColor Dis. 2011;27(2):233–41.
25. COLRAR. https://clinicaltrials.gov/ct2/show/NCT01423214.
26. Marks G, Mohiuddin M, Goldstein SD.Sphincter preservation for cancer of the distal rectum
using high dose preoperative radiation. Int JRadiat Oncol Biol Phys. 1988;15(5):1065–8.
27. Marks JH, Frenkel JL, D’Andrea AP, Greenleaf CE.Maximizing rectal cancer results: TEM and
TATA techniques to expand sphincter preservation. Surg Oncol Clin N Am. 2011;20(3):501–
20. viii–ix.
28. Whiteford MH, Denk PM, Swanström LL.Feasibility of radical sigmoid colectomy performed
as natural orice translumenal endoscopic surgery (NOTES) using transanal endoscopic microsurgery. Surg Endosc. 2007;21(10):1870–4.
29. Atallah S, Albert M, Larach S.Transanal minimally invasive surgery: a giant leap forward.
Surg Endosc. 2010;24(9):2200–5.
30. Fajardo AD, Hunt SR, Fleshman JW, Mutch MG.Transanal single-port low anterior resection
in a cadaver model. Surg Endosc. 2010;24(7):1765.
31. Sylla P, Sohn DK, Cizginer S, Konuk Y, Turner BG, Gee DW, etal. Survival study of natural
orice translumenal endoscopic surgery for rectosigmoid resection using transanal endoscopic microsurgery with or without transgastric endoscopic assistance in a swine model. Int JColor Dis. 2010;25(8):2022–30.
32. Bravo R, Trépanier JS, Arroyave MC, Fernández-Hevia M, Pigazzi A, Lacy AM.Combined
transanal total mesorectal excision (taTME)with laparoscopic instruments and abdominal robotic surgery in rectal cancer. Tech Coloproctol. 2017;21(3):233–5.
33. Motson RW, Whiteford MH, Hompes R, Albert M, Miles WFA, Expert Group. Current status
of trans-anal total mesorectal excision (TaTME) following the second international consensus conference. Color Dis. 2016;18(1):13–8.
34. Lelong B, de Chaisemartin C, Meillat H, Cournier S, Boher JM, Genre D, etal. A multicen-
tre randomised controlled trial to evaluate the efcacy, morbidity and functional outcome of endoscopic transanal proctectomy versus laparoscopic proctectomy for low-lying rectal cancer (ETAP-GRECCAR 11 TRIAL): rationale and design. BMC Cancer. 2017;30:1–8.
35. COLOR III. https://clinicaltrials.gov/ct2/show/NCT02736942.
36. OSTRiCh. https://tatme.ostrichconsortium.org.
37. NAPRC. https://www.facs.org/quality-programs/cancer/naprc.
38. Billingsley KG, Morris AM, Green P, Dominitz JA, Matthews B, Dobie SA, etal. Does sur-
geon case volume inuence nonfatal adverse outcomes after rectal cancer resection? JAm Coll Surg. 2008;206(6):1167–77.
39. Yeo HL, Abelson JS, Mao J, O’Mahoney PRA, Milsom JW, Sedrakyan A.Surgeon annual and
cumulative volumes predict early postoperative outcomes after rectal cancer resection. Ann Surg. 2017;265(1):151–7.
J. Fleshman and K. Wells

Index

A
Abdominal compartment syndrome (ACS), 115 Abdominoperineal excision (APE)
AR, 267
CRM, 265
local recurrence, 267, 271
pelvic dissection, 266
perineal dissection, 265
rectal cancer, 264 Abdominoperineal resection (APR), 318, 341
functional outcomes, 310
vs. ISR, 309
low rectal cancers, 301
vs. SPS, 302, 303 ACS Commission on Cancer (CoC), 376 Acute diverticulitis
DILALA, 123
emergency surgery, 121
end colostomy/HP, 122
generalized peritonitis, 121
gram-negative and anaerobic bacteria, 122
laparoscopic lavage and drainage, 124–126
LHP, 122
LLD, 122
LOLA and DIVA groups, 123
non-operative treatment, patients, 124
prevalence of, 121
primary anastomosis, 124
PubMed, 122
RCTs, 123
readmission rate, 123
sigmoidectomy, 123
three-stage operation, 121 Adenoma-associated lesion or mass (ALM), 44 Altemeier procedure, 163, 166–168 American Society of Colon and Rectal
Surgeons (ASCRS), 137, 194 Anal endosonography, 155, 156, 158 Anal manometry, 158
Anastomotic leak
assessments, 357 biomarker
disruption and luminal bacteria, 364 intestinal inammation, 363
intestinal ischemia, 362 categorization, 356 focal/segmental ischemia, 356 ghost ileostomy, 356 integrity, 355 intraoperative assessment, perfusion
assessing anastomotic
perfusion, 361, 362
ICG, 360, 361 local vascular insufciency/splanchnic
vasoconstriction, 356
mechanical completeness
air-leak tests, 358, 359
doughnuts, 357
intraoperative endoscopic
assessment, 359, 360 mechanisms, 356 meta-analysis, 358 microperfusion, 364 multifactorial, 355 perioperative morbidity, 355 rectal cancer, 355
Argon plasma coagulation (APC), 59 Articial bowel sphincter (ABS), 198, 199 Australian Laparoscopic Compared with open
Low Anterior Resection Trial
(ALaCaRT), 372
Autouorescence imaging (AFI), 40
B
Balloon expulsion test, 160 Balloon expulsion testing, 155 ‘Bottom-up’ or transanal approach, 275
© Springer International Publishing AG 2018 C.M. Schlachta, P. Sylla (eds.), Current Common Dilemmas in Colorectal Surgery,
https://doi.org/10.1007/978-3-319-70117-2
379
380
Index
Bowel preparation
and antisepsis, 11 antimicrobial therapy, 12 bulking agents, 12 CFU, 11 combined mechanical, oral and parenteral
preparation, 11 evidence-based practices, 11 history of
1860s–early1900s, 12, 13 1940s–1970s, 13 1980s–1990s, 13–14 2000–2010, 14, 15
National Surgical Quality Improvement
Project, 16 nonabsorbable enteral antibiotic use, 16 nonabsorbable sulfonamides, 12 NSQIP, 15 parenteral antibiotic prophylaxis, 15 postoperative infections, 11 prolonged ileus, 15 single-agent therapies, 12
Bowel resection, 178
C
C. difcile infection (CDI)
accurate and quick diagnosis, 108 antibiotic consumption, 108 community-acquired, 108 dened, 108 endoscopic conrmation, 109 indications, 110 loop ileostomy, 110 moderate, 108 nonoperative and operative approaches, 110 radiological tests, 109 surgery riming and role, 110 total colectomy with end ileostomy, 110
C. difcile-associated diarrhea (CDAD), 107 Chemoprevention, 51 Chemoradiation, 302, 303 Chemotherapy, 296 Chromoendoscopy (CE), 37–39 Circumferential radial margin (CRM), 333 Circumferential resection margin
(CRM), 265, 342
Clostridium difcile infection
antibiotic consumption, 108 CDAD and CDI, 107 CDI (see C. difcile infection (CDI)) clinical symptoms, 108 complicated/fulminant CDI, 108 description, 107
diagnosis, 108–109 endoscopic conrmation, 109 exotoxins, 108 morbidity and mortality, 107 radiological tests, 109 spores, 107
Colectomy
benign conditions, 207 extracorporeal anastomosis, 211 ileocolic anastomosis, 210 minimally invasive laparoscopic, 212 NSQIP, 213 perioperative outcomes, 212
Coloanal anastomosis (CAA)
anastomotic leak, 320 functional outcomes, 320 HCAA, 318 ISR, 319 QOL, 322 splenic exure, 313 SPS, 313 TC, 322
transverse coloplasty, 316 Coloanal reconstruction, 322 Colon surgery, 5, 207, 214 Colonic J-pouch (CJP), 314, 315, 319–323 Colonic lavage, 115–119 Colonic mucosal lesions
Kudo pit pattern classication, 58 Colonoscopic perforations, 101, 102 Colony-forming units (CFU), 11 Colorectal neoplasms
Paris classication, 58 Colorectal surgery
anastomotic leak rates after, 7
elective, 3, 14
enteral and parenteral antibiotics, 15
gut decontamination with oral
nonabsorbable antibiotics, 8 Nichols preparation, 16 parenteral antibiotics, 13 patients management, 21 rectal resections, 5 safe anastomosis without mechanical
preparation, 14 SSI, 5
Combined endoscopic laparoscopic surgery
(CELS), 70, 74
Complete clinical response (cCR)
MRI, 293, 295 nCRT, 292 WW, 293, 294
Complete pathological response (cPR), 289 Constipation
Index
381
anus and puborectalis, 160 clinicians, 159 colon transit study, 184 defecography, 160 digital rectal exam, 159 dyssynergia and obstructive defecation, 159 gastrointestinal complaints, 159 low-ber diet and promotility agents, 185 non-relaxing puborectalis/external anal
sphincter, 160 obstructive defecation, 160 Rome III criteria, 159 STARR and VR, 188
Covered perforations, 144 CRM, see Circumferential resection margin
(CRM)
Crohn’s colitis, 43, 50, 207
D
Damage control surgery (DCS), 122, 136, 137 Defecography
anatomic barriers identication, 156 defecation, 156 small bowel and colon opacication, 156
Delorme procedure, 166–168 Denonvilliers’ fascia, 371 Descending perineum syndrome, 189 Diarrhea
antibiotic-associated, 107 high-risk communities, 109 toxic megacolon and perforation, 108
Digital rectal examination (DRE), 290, 303 Distal resection margins (DRM), 280 Diverticular perforation, 98–101 Diverticulitis-laparoscopic lavage vs. resection
(DILALA), 98
Dutch Diverticular Disease (3D) Collaborative
Study, 134
Dysplasia
and colorectal cancer, 33 and neoplastic lesions, 34 personal history, 33 surveillance in IBD, 33 WLE exam, 39
Dysplasia management
chemoprevention, 51 CRN and CRC, 43 DALM and ALM, 44 detection, 44 disease-specic factors, 46 endoscopically invisible, 49, 50 high-resolution methods, 44 interval colonoscopic exams, 43
patient, disease and histologic
characteristics, 52 polypoid lesions, 44 pseudopolyps and scars, 44–46 risk factors, 46, 47 stricture, presence of, 46 surveillance intervals, 50, 51 surveillance program, 43 visible dysplasia, 44 visible lesions, 46–49
Dysplasia-associated lesion
or mass (DALM), 44
Dyssynergic defecation, 189
E
Early and intermediate recovery
ERPs, 25, 26
EHS classication, 252 Electromyography (EMG), 155 Emergency colectomy, 98 Emergency laparoscopic bowel surgery
anaesthetic consultation and strategic plan
discussion, 98 applications, 98–103 cholecystectomy and anti-reux
surgery, 97 colonoscopic perforations, 101, 102 diverticular perforation, 98–101 hand ports, 97 inammatory bowel disease, 101 obstructing right colon cancer, 99, 100 patient selection, 97, 98 small bowel obstruction, 102, 103 team composition, 97 trans-anal stapling, 98 ultrasonic and bipolar energy
sources, 97
Emergency surgery, 121 Endoluminal resection, 91 Endoscopic detection, see Inammatory bowel
disease (IBD)
Endoscopic mucosal resection (EMR)
technique efcacy and adverse events, 61 vs. ESD, 70, 74, 90, 91 Kudo pit pattern classication, 57, 58 laterally spreading polyps, 56 Paris classication, 57, 58 polyps, 57 preparation, 56, 57 resection techniques, 59–61 smooth “nongranular” type, 57
Endoscopic resection, 47, 48, 50
382
Index
Endoscopic submucosal dissection
(ESD), 48, 91 adenomas resection, 62 adoption, 62 advanced histology, 62 careful examination, specimens, 62 efcacy and complications, 70 electrosurgical knives, 62 endoscopic hemoclip placement, 68 endoscopic suturing device, 68 ESGE and JGES, 63 high-frequency EUS probes, 66 knives and hemostatic accessories, 66, 67 Kudo pit pattern classication, 63 magnication chromoendoscopy, 63 minimally invasive surgery, 74–77 morbid gastrectomy and
lymphadenectomy, 62 mucosal incision, 67 pediatric colonoscope, 66 recurrence after piecemeal lesions, 62 Sano capillary pattern, 65 steps in, 68, 69 submucosal dissection, 67 vessel coagulation, 67 virtual chromoendoscopy, 63
End-to-side (ETS), 315, 316, 321, 323 Enhanced recovery after surgery (ERAS)
pathway, 165
Enhanced recovery pathways (ERPs)
antibiotic prophylaxis and
thromboprophylaxis, 22 components, 22, 23 description, 22 early and intermediate recovery, 25, 26 initial randomized trials, 22, 23 late recovery, 27 perioperative interventions, 21, 22 perioperative period, 21 postoperative recovery, 23–25
Enterocele, 186, 187 Enterotomies, 222 Enterotomy closure, 224, 225 ETAP-GRECCAR 11 trial, 282, 375 European Association of Endoscopic Surgeons
(EAES), 137
European Organisation for Research and
Treatment of Cancer (EORTC), 27
European Society of Gastrointestinal
Endoscopy (ESGE), 63
External rectal prolapse (ERP)
LVR, 186 STARR, 188
Extralevator abdominoperineal excision
(ELAPE) abdominal part, 268 CRM, 270 external sphincter, 271 local recurrence, 271 mesorectum, 270 neurovascular bundles, 269 pelvic dissection, 268 perineal dissection, 268, 269
F
Fecal diversion, 190 Fecal incontinence (FI)
anal endosonography, 158 biofeedback, 158 defecography, 159 dened, 193 etiologies, 157, 193 maintenance of, 157 management strategies, 193 medical therapy, 157 physical exam, 157 SNS (see Sacral nerve stimulation (SNS)) solid/liquid feces loss, 157 validated surveys, 157
Fecal microbiota therapy (FMT)
mortality associated with FCDC, 119 recurrent CDI, 118 severity score, 118
FENIX magnetic sphincter augmentation
(MSA) system, 198, 200
Fermentable oligo-, di-, monosaccharides, and
polyols (FODMAP), 185
5-Fluorouracil (5-FU), 330 FOLFOX chemotherapy, 336 Foreign body reinforcement, 246–248 Free perforations, 144 French Jackson-Pratt drains, 124 Fuji Intelligent Chromoendoscopy (FICE), 40 Full-thickness local excision (FTLE), 301 Fulminant Clostridium difcile colitis (FCDC)
colonic ischemia and perforation, 113 description, 113 low gastrointestinal restoration rates, 113 medical management, 113 minimally invasive procedure, 114, 116 non-operative interventions, 118
FMT (see Fecal microbiota therapy
(FMT))
nasojejunal lavage (see Nasojejunal
lavage)
Index
383
operative and non-operative colon-
preserving options, 114
operative interventions, 115–117
loop ileostomy (see Loop ileostomy) Turnbull “Blowhole” procedure, 117, 118
surgical interventions, 114
G
Gastrointestinal Quality of Life Index
(GIQLI), 27
Grading of Recommendations, Assessment,
Development, and Evaluation (GRADE) system, 148
H
Hand-assisted laparoscopic surgery (HALS)
benign conditions, 207 colon and rectum, 209 colorectal surgery, 211–214 cost-conscious medical industry, 207 exposure, 209 GI tract continuity, 210 hand-assisted laparoscopic
port placement, 210, 211 ileocolic anastomosis, 210 intra-abdominal operations, 207 malignancy, 210 minilaparotomy incision, 211 minimally invasive operations, 208 multi-quadrant colorectal surgery, 207 non-colorectal laparoscopic operations, 208 operations, 210 operative time and conversion rates, 210
Hand-sewn coloanal anastomosis
(HCAA), 314, 318
Hand-sewn straight coloanal anastomosis, 317 Hartmann’s procedure (HP), 122 Hartmann’s vs. primary anastomosis, 133–136 Hemicolectomy, see Ileocolic/right
hemicolectomy
High-denition (HD) colonoscopy
technologies, 36
High-grade dysplasia (HGD), 50 High-resolution magnetic
resonance imaging, 343
Hinchey classication system, 130 Hypofractionation, 332
I
Ileocecal interposition (ICI), 318 Ileocolic/right hemicolectomy
anatomy, 220–222 Crohn’s disease, 223 guidelines and positioned supine, 220 intracorporeal resection, 221, 222 isoperistaltic anastomosis, 222
trocar placement, 221 Indocyanine green (ICG), 360, 361 Indocyanine green uorescence angiography
(ICG-FA), 360 Inferior mesenteric artery (IMA), 132 Inammatory bowel disease (IBD)
colitis histology, 33 colon cancer and dysplasia surveillance,
34–36
dysplasia and colorectal cancer, 33 endoscopic removal, dysplastic
lesions, 33
histologic inammatory activity, 33 patients’ risk factors, 34 surveillance examination, 33 WLE (see White-light
endoscopy (WLE)) Injectable bulking agents, 194, 199 Internal rectal prolapse (IRP)
LVR, 186 STARR, 188
Intersphincteric resection (ISR)
abdominal dissection, 345, 346 advantages, 348 chemoradiotherapy, sphincter-preserving
surgery, 344, 345
feasibility and morbidity, 349 functional results, 350 oncological results, 349 perineal dissection, 346–348 perineal transanal approach, 350 rectal cancer
classication, 343, 344 management, 341 oncological rules, 341, 342
surgical management, 342, 343 Interval colectomy, 143–147 Interval resection, 144, 145, 147 Intestinal antisepsis, 11 Intracorporeal anastomosis (IC)
demographics, 218 disadvantages, 220 intraoperative, 218, 219 Pfannenstiel, 219
postoperative, 218, 219 Intraluminal microdialysis catheter, 362 Intraoperative bowel perforation, 270 Intussusception, 186 Isoperistaltic anastomosis, 222
384
Index
J
Japanese Gastrointestinal Endoscopy Society
(JGES), 63
K
Kaunas University of Medicine, 335 Keyhole technique, 253, 257, 258
L
Laparoscopic colectomy, 137 Laparoscopic colorectal surgery, 227, 228, 235 Laparoscopic Hartmann resection, 99 Laparoscopic Hartmann’s procedure (LHP), 122 Laparoscopic ileocolic, see Ileocolic/right
hemicolectomy
Laparoscopic intracorporeal
anastomosis (IC), 217
Laparoscopic lavage and drainage (LLD), 122,
124–126
Laparoscopic ventral mesh rectopexy
(LVMR), 171, 174 Laparoscopic ventral rectopexy (LVR), 187, 188 Laparoscopic-assisted colorectal surgery, 74 Laparoscopic-assisted extracorporeal
anastomosis (EC), 217 Laparoscopy
functional outcomes, 374 oncologic outcomes, 372, 373 principles, 369–372 short-term outcomes, 373
TME, 369 Large colon polyps, 56 Laser Doppler owmetry (LDF), 362 Late recovery
ERPs, 27 Lavage
laparoscopic, 147
surgical re-intervention, 147 Local recurrence (LR), 302 Loop ileostomy
ACS, 116
Foley catheter, 115
historical TAC and experimental groups, 115
indications, 115
laparotomy/diagnostic laparoscopy, 117
with lavage technique, 115
prospective national Canadian registry, 116
vs. total abdominal colectomy, 116 Low anterior resection (LAR), 342 Low anterior resection syndrome, 318, 350 Low rectal cancers, 341–348, 350 Low-grade dysplasia (LGD), 50
Lysozyme, 363
M
Macroperforation, 146–148 Mesorectum, 370 Microbiome
human health and disease, 16
Microperforation
ACPGBI and WSES guidelines, 146 adverse outcomes, 146 description, 145 interval colectomy recommendations, 146
mesocolic abscesses, 146 Miles operation, 263 Minimally invasive approach, 376 Molecular imaging, 294 Mucosectomy, 314 Multi-agent systemic chemotherapy, 330 Multidimensional Fatigue Inventory 20
(MFI-20), 27
N
Narrow band imaging (NBI), 39, 40 Narrow-band imaging International Colorectal
Endoscopic (NICE), 66
Nasojejunal lavage
early intervention, 118
feasibility randomized trial, 118 National Accreditation Program for Rectal
Cancer (NAPRC), 376 National Cancer Database (NCDB), 374 National Comprehensive Cancer Network
Guidelines, 329 National Surgical Quality Improvement
Program (NSQIP), 7, 212 National Surgical Quality Improvement
Project (NSQIP), 15 Natural orice specimen extraction (NOSE)
colectomy
advantages and disadvantages, 232 bowel anastomosis, 227 conventional medial-to-lateral approach, 229 description, 227 difculties and complications, 232, 233 heterogeneity and bias, 228 indications, 228, 229 proximal colotomy, 230 sigmoid resection with transrectal
extraction, 228 Natural orice transluminal endoscopic
surgical (NOTES) procedures, 228,
275, 302
Index
385
Neoadjuvant chemoradiotherapy (nCRT), 289,
292, 295, 302
Neoplasia
colorectal, 43 dened, 51 dysplasia surveillance, 43
metachronous development, 50 Nonabsorbable antibiotics, 12, 13, 16 Nonpolypoid lesions, 47, 48
O
Obstructed defecation syndrome (ODS)
abnormal function, 183
balloon expulsion, 184
blood testing, 184
conservative treatments, 185
dened, 183
descending perineum syndrome, 189
enterocele, 186, 187
fecal diversion, 190
uoroscopic defecography during the
evacuation phase, 184 history and examination, 183–185 pelvic oor dyssynergia, 189 rectal hyposensitivity, 190 rectocele (see Rectocele) screening colonoscopy, 184 sigmoidocele, 186
Obstructing right colon cancer, 99, 100 Obstructive defecation, 159, 160 Obstructive defecation syndrome (ODS), 159 Oligometastatic disease, 337 Oral mechanical bowel preparation (OMBP)
elective colorectal surgery, 3 vs. enema/no preparation, 3–6 European and Canadian surgical societies, 3 GRECCAR III randomized trial, 5 gut decontamination with oral
nonabsorbable antibiotics, 8 laparoscopic resection, 5 Mayo Clinic group, 5 NSQIP, 7 oral antibiotics, 7 SSI rates, 3 Veterans Affairs (VA), 7 with/without enema vs. enema/no
preparation, 5, 6
OSTRiCh, 376
P
Parastomal hernia (PSH)
conservative treatment, 252
denition, 242 EHS classication, 252 foreign body reinforcement, 246–248 healthcare utilization, 242 incidence, 242 intestinal stoma creation, 241 laparoscopy, 253 local repair with mesh, 253, 255 local suture repair, 252, 253 on patients, 243 physical examination, 251 recurrence repair of, 244 risk factors, 243–244 stoma creation technique, 245, 246 stoma formation, 251 stoma placement, 244 sugarbaker technique, 253, 255, 258 surgical strategy, 252, 258 symptoms, 251
Parenteral antibiotics
colorectal surgery, 13, 14 enteral and, 15
oral antibiotics, 14 Partial mesorectal excision (PME), 342 Pathologic complete response (pCR), 333 Patient-controlled analgesia (PCA), 307 Pelvic oor dyssynergia, 189 Pelvic organ prolapse (POP) disorders, 172 Perforated diverticulitis
adjacent organs/omentum, 129
ASN, DSS and EAES guidelines, 148
cancer risk, 148, 149
classication, 130
colo-colonic anastomosis, 132
CT imaging, 131
DCS, 136, 137
emergency surgery, 133
end-colostomy/primary anastomosis, 144
generalized peritonitis, 131
historic management, 131, 132
IMA and SRA, 132
immunosuppressed patients, 129, 137, 138
indications, 129
interval colectomy, 144
laparoscopic colectomy, 137
laparoscopic lavage, 131
limitations, 131
macroperforation, 146–148
microperforation, 145, 146
microscopic and macroscopic, 144
optimal/cutoff number, recurrences, 145
“prophylactic” colectomy, 145
proximal and distal margins, 132
sigmoid colon, 129